Clinical Trials Insight: 700036224
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2009
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Therapeutic Use
- Sponsors Biota Holdings
- 14 Jun 2009 Planned number of patients changed from 240 to 41 actually enrolled, according to Biota Holdings media release.
- 11 Jun 2009 Biota Holdings announced this study was successful in demonstrating proof-of-concept in humans according to a company media release.
- 14 Aug 2008 New trial record.